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• The epithelial-mesenchymal transition (EMT) is a process
activated during cancer that allows cells to acquire migratory
capacities, stem cell properties, and increased metastatic
potential.
• Epithelial cells possess more E-cadherin, an epithelial
protein, and cytokeratin (keratin protein in tissues).
• Mesenchymal cells have more N-cadherin, a
mesenchymal extracellular protein, and vimentin
(intermediate filament protein).
• Along the EMT spectrum, there exists a hybrid E/M cell that
exhibits advantageous plasticity, the ability to transit between
states.
• Transforming growth factor-beta 1 (TGFβ1) induces EMT
through ECM remodeling, and SB43152 inhibits the TGFβ1
signaling pathway, pushing cells to undergo mesenchymalepithelial transition (MET).
• The cellular response to EMT-MET induction is unknown
within cancer cells without plasticity.
• Another facet of hybrid E/M cells is the expression of epithelial
and mesenchymal structural cellular markers, such as
cytokeratin and vimentin filament proteins, respectively.
• The putative interaction of these markers is not understood in
hybrid E/M cells.
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Figure 2. D2.A1 and D2.OR cells were assessed for epithelial
and mesenchymal markers using flow cytometry to establish their
EMT status. D2.A1 predominantly co-expresses the epithelial
and mesenchymal marker (EN+), thereby making it a hybrid E/M
model. However, the majority of the D2.OR cells only express the
mesenchymal marker (N+).
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Figure 4. The D2.OR and D2.A1 cells were imaged through
immunofluorescent microscopy for structural markers, Keratin
14 (red, epithelial) and vimentin (green, mesenchymal).
D2.OR cells predominantly expressed vimentin independent
of treatment with TGFβ1 or SB43154. D2.A1 cells expressed
a co-localization of vimentin and keratin when untreated.
Once treated with TGFβ1, D2.A1 cells attained mesenchymallike properties and expressed vimentin, and they gained
epithelial-like properties expressing keratin under the
treatment of SB43154.
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Figure 1. The epithelial-mesenchymal transition
includes extracellular matrix remodeling of filament
proteins, cytokeratin and vimentin. The hybrid E/M cell
state likely exhibits a co-localization of the epithelial
marker (cytokeratin) and the mesenchymal marker
(vimentin).
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•

I hypothesize that hybrid E/M cells with plasticity will be more
resilient to apoptotic stress altering the EMT state relative to
non-plastic cells, and they will possess co-expression of
vimentin and cytokeratin filaments.

Materials & Methods
Reagents
•TGFβ1
•SB431542 (TGFβ1 inhibitor)
•Caspase-3/7 green dye (apoptotic marker)
•Keratin 14 antibody
•Vimentin antibody
ØFlow Cytometry was used to collect single cells of D2.A1 and
D2.OR for scanning of E-Cadherin and N-Cadherin markers.
ØD2.A1 and D2.OR cells were imaged for confluence and
Caspase-3/7 activity by Incucyte® for six days under the
conditions of no treatment, treatment with TGFβ1, and
treatment with SB431542.
ØThe D2.A1 and D2.OR cells were then stained to be imaged
for Keratin 14 (red) and Vimentin (green) using microscopy.

•

Figure 3. (A) D2.A1 and D2.OR cells were treated with TGFβ1 and
SB43154 to determine their capabilities to transit between states on
the E/M spectrum. Caspase-3/7 green dye was used to showcase cell
viability through Incucyte® data. D2.OR cells faced higher apoptosis
levels, whereas D2.A1 cells had a higher viability. (B) Normalized
caspase activity, calculated as Caspase Levels/Confluency, was
determined by the Incucyte® over time for D2.A1 and D2.OR cells per
condition of treatment.

•

Apoptotic resistance within D2.A1 hybrid E/M cells in
comparison to D2.OR mesenchymal cells exemplifies the
advantageous flexibility held by cancer cells with plasticity
on the E/M spectrum.
The co-localization of Keratin 14 and vimentin expressed
by D2.A1 cells supports an understanding of the nature of
structural plasticity.
The ability for D2.A1 cells to express mesenchymal-like
features with TGFβ1 and become epithelial-like under the
treatment of SB43154 demonstrates the hybrid E/M cellular
adaptivity within a tumor microenvironment.
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